Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Characterization of a Cynomolgus Macaque Model of Pneumonic Plague for Evaluation of Vaccine Efficacy.

Fellows P, Price J, Martin S, Metcalfe K, Krile R, Barnewall R, Hart MK, Lockman H.

Clin Vaccine Immunol. 2015 Sep;22(9):1070-8. doi: 10.1128/CVI.00290-15. Epub 2015 Jul 29.

2.

Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.

Aichinger G, Grohmann-Izay B, van der Velden MV, Fritsch S, Koska M, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN.

Clin Vaccine Immunol. 2015 Jan;22(1):46-55. doi: 10.1128/CVI.00275-14. Epub 2014 Oct 29.

3.

Preclinical safety assessment of a recombinant plague vaccine (rF1V).

Price JL, Manetz TS, Shearer JD, House RV.

Int J Toxicol. 2013 Sep-Oct;32(5):327-35. doi: 10.1177/1091581813497405. Epub 2013 Aug 1.

PMID:
23908395
4.

Establishment of a Swiss Webster mouse model of pneumonic plague to meet essential data elements under the animal rule.

Fellows P, Lin W, Detrisac C, Hu SC, Rajendran N, Gingras B, Holland L, Price J, Bolanowski M, House RV.

Clin Vaccine Immunol. 2012 Apr;19(4):468-76. doi: 10.1128/CVI.05591-11. Epub 2012 Feb 15.

5.

Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B).

Shearer JD, Manetz TS, House RV.

Vaccine. 2012 Mar 2;30(11):1917-26. doi: 10.1016/j.vaccine.2012.01.035. Epub 2012 Jan 23.

PMID:
22269871
6.

Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges.

Hart MK, Saviolakis GA, Welkos SL, House RV.

Adv Prev Med. 2012;2012:731604. doi: 10.1155/2012/731604. Epub 2011 Oct 17.

7.

Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V).

Fellows P, Adamovicz J, Hartings J, Sherwood R, Mega W, Brasel T, Barr E, Holland L, Lin W, Rom A, Blackwelder W, Price J, Morris S, Snow D, Hart MK.

Vaccine. 2010 Nov 16;28(49):7748-56. doi: 10.1016/j.vaccine.2010.09.062. Epub 2010 Oct 15.

PMID:
20920572
8.

Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B).

Shearer JD, Vassar ML, Swiderski W, Metcalfe K, Niemuth N, Henderson I.

Vaccine. 2010 Oct 21;28(45):7313-8. doi: 10.1016/j.vaccine.2010.08.076. Epub 2010 Sep 1.

PMID:
20816903
9.

Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.

Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL.

Vaccine. 2010 Apr 19;28(18):3143-51. doi: 10.1016/j.vaccine.2010.02.056. Epub 2010 Mar 1.

10.

Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB.

Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL.

Vaccine. 2010 Jan 22;28(4):1031-40. doi: 10.1016/j.vaccine.2009.10.126. Epub 2009 Nov 13.

11.

A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV).

Fine DL, Jenkins E, Martin SS, Glass P, Parker MD, Grimm B.

J Virol Methods. 2010 Feb;163(2):424-32. doi: 10.1016/j.jviromet.2009.11.006. Epub 2009 Nov 10.

12.

Telemetric analysis to detect febrile responses in mice following vaccination with a live-attenuated virus vaccine.

Martin SS, Bakken RR, Lind CM, Reed DS, Price JL, Koeller CA, Parker MD, Hart MK, Fine DL.

Vaccine. 2009 Nov 16;27(49):6814-23. doi: 10.1016/j.vaccine.2009.09.013. Epub 2009 Sep 15.

13.

Multidimensional immunomodulation.

House RV, Hastings KL.

J Immunotoxicol. 2004 Apr;1(2):123-9. doi: 10.1080/15476910490503646. No abstract available.

PMID:
18958645
14.

Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates.

Fine DL, Roberts BA, Terpening SJ, Mott J, Vasconcelos D, House RV.

Vaccine. 2008 Jun 25;26(27-28):3497-506. doi: 10.1016/j.vaccine.2008.04.044. Epub 2008 May 7.

PMID:
18508163
15.

Immunotoxicology IV - innovative methods and applications for risk assessment in pharmaceutical development: introduction to the conference.

House RV.

J Immunotoxicol. 2008 Jan;5(1):1. doi: 10.1080/15476910801897300. No abstract available.

PMID:
18382851
16.

Development of a recombinant vaccine against aerosolized plague.

Morris SR.

Vaccine. 2007 Apr 20;25(16):3115-7. Epub 2007 Jan 30.

PMID:
17291640
17.

Systems integration: an effective and innovative response to emerging biological threats.

House RV.

Vaccine. 2007 Apr 20;25(16):3170-4. Epub 2007 Jan 19.

PMID:
17270323
18.

Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses.

Fine DL, Roberts BA, Teehee ML, Terpening SJ, Kelly CL, Raetz JL, Baker DC, Powers AM, Bowen RA.

Vaccine. 2007 Feb 26;25(10):1868-76. Epub 2006 Oct 27.

PMID:
17240002
19.

Clinical efficacy of intramuscular vaccinia immune globulin: a literature review.

Hopkins RJ, Lane JM.

Clin Infect Dis. 2004 Sep 15;39(6):819-26. Epub 2004 Aug 23. Review.

PMID:
15472814
20.

Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers.

Hopkins RJ, Kramer WG, Blackwelder WC, Ashtekar M, Hague L, Winker-La Roche SD, Berezuk G, Smith D, Leese PT.

Clin Infect Dis. 2004 Sep 15;39(6):759-66. Epub 2004 Aug 23.

PMID:
15472804

Supplemental Content

Loading ...
Support Center